Results 51 to 60 of about 461 (138)

From amoeboid myosin to unique targeted medicines for a genetic cardiac disease

Frontiers in Physiology
The importance of fundamental basic research in the quest for much needed clinical treatments is a story that constantly must be retold. Funding of basic science in the USA by the National Institutes of Health and other agencies is provided under the ...
James A. Spudich
doaj   +1 more source

Safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy: A 36‐week analysis from FOREST‐HCM

European Journal of Heart Failure, Volume 26, Issue 9, Page 1993-1998, September 2024.
Aims The aim of this study was to report safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy (nHCM) over 36 weeks in the ongoing FOREST‐HCM trial. Methods and results Patients were started on aficamten 5 mg daily, with doses adjusted in 5‐mg increments (5–20 mg) at ≥2‐week intervals according to site‐read left ...
Ahmad Masri, Roberto Barriales‐Villa, Perry Elliott, Michael E. Nassif, Artur Oreziak, Anjali T. Owens, Albree Tower‐Rader, Stephen B. Heitner, Stuart Kupfer, Fady I. Malik, Chiara Melloni, Lisa Meng, Jenny Wei, Sara Saberi, on behalf of the FOREST‐HCM Investigators   +14 more
wiley   +1 more source

A systematic review of present and future pharmaco‐structural therapies for hypertrophic cardiomyopathy

Clinical Cardiology, Volume 47, Issue 1, January 2024.
Hypertrophic cardiomyopathy (HCM) is an increasingly recognized genetic condition that is accompanied by a heterogeneous phenotype. The presence of outflow tract obstruction carries an increased risk for the development of heart failure, arrhythmias, and sudden cardiac death.
Mariem A. Sawan, Sindhu Prabakaran, Melroy D'Souza, Omid Behbahani‐Nejad, Matthew E. Gold, Byron Robinson Williams, Ozlem Bilen   +6 more
wiley   +1 more source

Magnetic resonance imaging evaluation of the effects of myosin inhibitors (mavacamten and aficamten) in hypertrophic cardiomyopathy: a systematic review and case report

Monaldi Archives for Chest Disease
Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder, affecting approximately 1 in 250 individuals. It is defined by unexplained left ventricular (LV) hypertrophy in the absence of other identifiable cardiac or systemic causes.
Carolina Bernardes, João Gomes Carvalho, Patrícia Rodrigues, Manuela França   +3 more
doaj   +1 more source

Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy [PDF]

Background/Aims: Obstructive HCM (oHCM) affects people across all geographic regions, ethnicities, and socioeconomic groups. In the SEQUOIA-HCM trial (NCT05186818), aficamten, an oral selective cardiac myosin inhibitor, improved exercise capacity ...
Hagège, Albert A., Masri, Ahmad, Cardim, Nuno, Kulac, Ian J., Abraham, Theodore, Tfelt-Hansen, Jacob, Düngen, Hans-Dirk, Maron, Martin S., Kupfer, Stuart, Arad, Michael, Michels, Michelle, Oreziak, Artur, Jacoby, Daniel L., Solomon, Scott D., Claggett, Brian L., Heitner, Stephen B., SEQUOIA-HCM Investigators, Ma, Chang-Sheng, Barriales‑Villa, Roberto, Coats, Caroline J., Merkely, Bela, Garcia-Pavia, Pablo, Olivotto, Iacopo   +22 more
core   +1 more source

How effective is disopyramide in treating pediatric hypertrophic cardiomyopathy? State of the art and future directions

Monaldi Archives for Chest Disease
Pediatric hypertrophic cardiomyopathy (HCM) has a wide range of clinical manifestations. Left ventricular outflow tract obstruction (LVOTO) at rest is present in up to one-third of children with HCM, with a further 50-60% of symptomatic children ...
Karin Del Vecchio, Caterina Rizzardi, Alice Pozza, Francesco Prati, Luisa Ye, Alessia Fattoretto, Elena Reffo, Giovanni Di Salvo   +7 more
doaj   +1 more source

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Ahmad Masri, Iacopo Olivotto
doaj   +1 more source

Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials

Open Heart
Background Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes.
Ayesha Aman, Arfa Akram, Bisma Akram, Momina Maham, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Furqan Yaqub   +7 more
doaj   +1 more source

Efficacy and safety of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4 [PDF]

Background This open-label phase 2 trial evaluated the safety and efficacy of aficamten in patients with nonobstructive hypertrophic cardiomyopathy (nHCM). Methods Patients with symptomatic nHCM (left ventricular outflow tract obstruction gradient ≤
Sohn, Regina L., Sohn, Regina L, Nagueh, Sherif F, Malik, Fady I, Owens, Anjali T, Watkins, Hugh, Jacoby, Daniel L., Malik, Fady I., Solomon, Scott D., Nagueh, Sherif F., Heitner, Stephen B., Wohltman, Amy, Solomon, Scott D, Heitner, Stephen B, Jacoby, Daniel L, Tower-Rader, Albree, Coats, Caroline J., Kramer, Christopher M., Garcia-Pavia, Pablo, Wong, Timothy C, Masri, Ahmad, Abraham, Theodore P, Fifer, Michael A, Meng, Lisa, Saberi, Sara, Abraham, Theodore P., Sherrid, Mark V., Rader, Florian, Sherrid, Mark V, Kupfer, Stuart, Maron, Martin S., Barriales-Villa, Roberto, Maron, Martin S, Owens, Anjali T., Kramer, Christopher M, Wong, Timothy C., REDWOOD-HCM Investigators, Coats, Caroline J, Fifer, Michael A., Choudhury, Lubna, Olivotto, Iacopo   +40 more
core   +1 more source

Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy:SEQUOIA-HCM Baseline Characteristics and Study Design [PDF]

Patients with obstructive hypertrophic cardiomyopathy (oHCM) have increased risk of arrhythmia, stroke, heart failure, and sudden death. Contemporary management of oHCM has decreased annual hospitalization and mortality rates, yet patients have worsening
.Jacoby, Daniel L, Cardim, Nuno, Malik, Fady I, Owens, Anjali T, Düngen, Hans-Dirk, Düngen, Hans Dirk, Oreziak, Artur, Michels, Michelle, Jacoby, Daniel L., Malik, Fady I., Lee, Matthew M Y, Heitner, Stephen B., Wohltman, Amy, Ma, Chang Sheng, Michels, Michelle; id_orcid, Heitner, Stephen B, Jacoby, Daniel L, Ma, Chang-Sheng, Coats, Caroline J., Lewis, Gregory D, Garcia-Pavia, Pablo, Watkins, Hugh C, Watkins, Hugh C., Lee, Matthew M.Y., Hagège, Albert A., Masri, Ahmad, Abraham, Theodore P, Meng, Lisa, Abraham, Theodore P., Tfelt-Hansen, Jacob, Maron, Martin S., Veselka, Josef, Kupfer, Stuart, Arad, Michael, Hagège, Albert A, Maron, Martin S, Owens, Anjali T., SEQUOIA-HCM Investigators, Coats, Caroline J, Choudhury, Lubna, Lewis, Gregory D., Olivotto, Iacopo   +41 more
core   +2 more sources